Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company specializing in the development of innovative therapeutics in inflammation and immunology, alongside a contract development and manufacturing organization (CDMO) business. The company operates at the intersection of drug discovery and biopharmaceutical services, leveraging its expertise in antibody-based therapies and manufacturing capabilities to address unmet medical needs in dermatological and inflammatory conditions. Its pipeline includes novel monoclonal antibodies and NanoAbs, a platform of nanosized antibody fragments with potential applications across multiple therapeutic areas.

Scinai Immunotherapeutics Ltd. generates revenue primarily through its CDMO business, which provides integrated development and manufacturing services to small and emerging biotech companies. These services include analytical method development, process optimization, and cGMP manufacturing for clinical-stage biologics and small molecules. The company also pursues non-dilutive funding, such as grants, to advance its internal research and development programs, which focus on therapeutic candidates like PC111 and NanoAb-based treatments for psoriasis, pemphigus, and other inflammatory diseases. While the CDMO segment currently drives revenue, the company’s long-term growth may depend on the successful commercialization of its proprietary drug candidates.

The company operates through the following segments:

• Scinai R&D: This segment focuses on the discovery and development of innovative therapeutics in inflammation and immunology. It includes the PC111 program, a fully human monoclonal antibody targeting severe dermatological conditions such as pemphigus, Stevens-Johnson Syndrome, and toxic epidermal necrolysis. Additionally, the segment advances a pipeline of NanoAbs, nanosized antibody fragments developed in collaboration with the Max Planck Society and the University Medical Center Göttingen, targeting clinically validated pathways like IL-17 and IL-13 for conditions such as psoriasis, psoriatic arthritis, and asthma. The R&D segment also evaluates strategic acquisitions and in-licensing opportunities to expand its therapeutic portfolio.

• Contract Development and Manufacturing Organization (CDMO): Operating through the subsidiary Scinai Biopharma Services Ltd., this segment provides end-to-end development and manufacturing services to biopharmaceutical clients. Services include early-stage analytical and process development, cGMP manufacturing for biologics and small molecules, and fill-and-finish operations. The CDMO business leverages facilities in Jerusalem and Yavne, Israel, to support clients from preclinical development through clinical-stage production. The segment also benefits from a strategic collaboration with Recipharm, enabling lifecycle support for client programs from early development to late-stage manufacturing.

Scinai Immunotherapeutics Ltd. occupies a niche position within the biopharmaceutical industry, competing with both large pharmaceutical companies and specialized biotech firms in the development of antibody-based therapeutics. Its competitive advantages include a dual business model that combines proprietary R&D with CDMO services, providing operational flexibility and revenue diversification. The company’s NanoAbs platform, developed in partnership with leading academic institutions, offers potential advantages such as strong binding affinity, thermal stability, and flexible administration routes, which may differentiate its pipeline from traditional monoclonal antibodies. Additionally, its CDMO business benefits from advanced manufacturing capabilities and a strategic collaboration with Recipharm, positioning it as a preferred partner for early-stage biotech companies. Key competitors include firms developing IL-17 and IL-13 inhibitors, as well as CDMO providers with similar service offerings.

The company’s customer base is divided between its CDMO and R&D segments. The CDMO business primarily serves small and emerging biotechnology companies, particularly in Israel and the United States, providing development and manufacturing services for clinical-stage programs. Specific client names are not disclosed, but the segment has secured multiple engagements, including repeat projects and contracts under negotiation. The R&D segment, while not yet commercialized, targets patients with severe dermatological and inflammatory conditions, such as pemphigus and psoriasis, where existing treatments are limited or associated with significant side effects. Future commercialization efforts may involve partnerships with pharmaceutical companies equipped to market and distribute its therapeutic candidates.